Meletios Dimopoulos, MD

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses a study analyzing ibrutinib (Imbruvica) and rituximab (Rituxan) treatment for patients with Waldenstrom macroglobulinemia (WM). The research was presented at the 2018 ASCO Annual Meeting.